Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Superparamagnetic Iron Oxide for Sentinel Lymph Node Localization in Patients With Cutaneous Melanoma, a Randomized Phase III Multi-center Non- Inferiority Trial: MagMen-II

NCT07552597 is registered in ClinicalTrials.gov with Vastra Gotaland Region as lead sponsor.

NCT NCT07552597
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07552597 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Superparamagnetic Iron Oxide for Sentinel Lymph Node Localization in Patients With Cutaneous Melanoma, a Randomized Phase III Multi-center Non- Inferiority Trial: MagMen-II
Lead sponsor
Vastra Gotaland Region
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
December 31, 2030
Enrollment
254 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin cancer)